Product Type
Antibody
Description
C5 is synthesized as a single polypeptide chain in the liver and is present in serum at a concentration of 50-80 μm/ml. Before secretion, the molecule is glycosylated and secreted into the plasma as a 190 kDa glycoprotein, which is composed of disulfide-linked α-chain (111 kDa) and β-chain (75 kDa). In functional complement tests, monoclonal antibody BB5.1 has been shown to precipitate two chains of C5 from normal mouse serum and inhibit C5-dependent hemolysis. In addition, during heart and kidney transplantation, BB5.1 administration completely inhibited the terminal complement activity of antibody-mediated rejection (AMR) in the murine model. In another mouse model, the pretreatment and intervention of monoclonal antibody BB5.1 both attenuate the disease development during glomerulonephritis induced by anti-MPO IgG. BB5.1 prevents C5 activation can prevent renal ischemia-reperfusion injury by inhibiting late-stage cell apoptosis and inflammation. In lupus disease, anti-IL-10/anti-C5 (BB5.1) combination therapy can both prevent and reduce the impact of humoral immune response.
Disease
Infectious diseases
Size
100 µg
Immunogen
Purified C5
Species
Mouse
Cross reactivity
Rat
Clonality
Monoclonal
Clone Number
BB5.1
Buffer
PBS and 0.1% BSA.
Application
Frozen sections, Functional studies, Immuno assays, Immuno fluorescence, Immuno precipitation, Paraffin sections
Application Notes
The diluent used depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution. The typical initial working dilution is 1:50.
Storage Instructions
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Alternative Names
Complement C5; Hemolytic complement
